OVERCOME
2013
PreventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies
In 90 patients with malignant haemopathies undergoing intensive chemotherapy or autologous stem-cell transplantation, enalapril plus carvedilol started before chemotherapy preserved left ventricular ejection fraction and reduced death or heart failure at 6 months compared with no cardioprotective treatment.
Result
Primary endpoint: Absolute change in left ventricular ejection fraction at 6 months
LVEF unchanged with treatment but reduced in controls (between-group difference −3.1 %; p=0.035). Death or heart failure 6.7 % vs 22 % (p=0.036).
- Subtopic
- Neurohormonal prophylaxis
- Design
- Randomised controlled trial with an untreated control group
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2022 Cardio-Oncology
- Source
- Bosch X, Rovira M, Sitges M, et al. J Am Coll Cardiol. 2013;61(23):2355-2362.doi 10.1016/j.jacc.2013.02.072
Discussion & critique
Very small, single-centre, with an untreated rather than placebo control and a composite built on few events, so the clinical benefit is fragile. It is the only randomised cardioprotection trial to reduce a clinical composite of death or heart failure and is the strongest pillar of combined ACE-inhibitor plus beta-blocker prophylaxis.